Page Menu

Metabolism and Physiology Department Metrics

View the clinical trials, grants and publications from the Department of Metabolism and Physiology.

Clinical Trials
CLINICAL TRIAL 19989
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Condition: Gastrointestinal Tumor
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Xeloda (capecitabine); capecitabine (); gemcitabine ()

CLINICAL TRIAL 20832
A Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms
Condition: Genitourinary
Intervention:

Grants
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Perturbing the Evolutionary Drivers of Targeted Therapy Resistance in NSCLC
    Sponsor: Amer Cancer Society
    PI:Marusyk, A.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
  • Therapeutic strategies for KEAP1/NRF2 mutant lung cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.
  • Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
    Sponsor: Nat Institutes of Health
    PI:Marusyk, A.
  • Impact of Stromal Architecture on the Response of Lung Cancers to Targeted Therapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Metabolic basis of the NADPH-independent disulfide reductase system in mouse liver
    Sponsor: Nat Institutes of Health
    PI (MPI):DeNicola, G.
  • Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Effects of novel glucagon-like peptide 1 receptor (GLP-1R) agonists on comorbidities in Alzheimer's disease with diabetes mellitus.
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:McDonald, P.
  • Pyridine Nucleotides: Missing Link between Aging and Lung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.,CO-PI:Gomes, A.
  • Evolution of Evolability Under Targeted Therapies
    Sponsor: Moffitt Cancer Center
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Predicting Dose Maps Adaptive Sterotatic Radiotherapy of Breast Cancer Metastases of the Brain St of FL COE Pilot Project 2
    Sponsor: Moffitt Cancer Center
    PI:Raghunand, N.,CO-PI:Ahmed, K.
  • Conjugates for Detection of Breast Cancer Nodal Metastasis
    Sponsor: Moffitt Cancer Center
    PI:Morse, D.,CO-PI:Luca, V.
  • Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
    Sponsor: US Army
    PI:Morse, D.
  • Impact of extracellular glutathione catabolism on triple-negative breast cancer
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • A High Content Screening Platform for High Throughput, High Content Imaging and Analysis
    Sponsor: Nat Institutes of Health
    PI (Contact):McDonald, P.
  • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Smalley, I.
  • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Tumor-Stroma Metabolic Crosstalk in Melanoma Brain Metastases
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.,CO-PI:Chen, A.
  • Tumor-stroma metabolic crosstalk in melanoma brain metastases
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Smalley, I.
  • Sensitizing leptomeningeal melanoma to checkpoint inhibitor therapy
    Sponsor: Moffitt Cancer Center
    PI (Contact):Smalley, I.
  • IND enabling studies for rare skin cancer targeted alpha particle therapy”.
    Sponsor: Moffitt Cancer Center
    PI:Morse, D.
Publications
  • Van Oss SB, Parikh SB, Coelho NC, Wacholder A, Belashov I, Zdancewicz S, Michaca M, Xu J, Kang YP, Ward NP, Yoon SJ, McCourt KM, McKee J, Ideker T, VanDemark AP, DeNicola GM, Carvunis AR. On the illusion of auxotrophy: met15Δ yeast cells can grow on inorganic sulfur, thanks to the previously uncharacterized homocysteine synthase Yll058w. J Biol Chem. 2022 Dec.298(12):102697. Pubmedid: 36379252. Pmcid: PMC9763685.
  • Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther. 2022 Dec.29(12):1840-1846. Pubmedid: 35332245. Pmcid: PMC9508287.
  • Maudsley S, Walter D, Schrauwen C, Van Loon N, Harputluoğlu İ, Lenaerts J, McDonald P. Intersection of the Orphan G Protein-Coupled Receptor, GPR19, with the Aging Process. Int J Mol Sci. 2022 Nov.23(21). Pubmedid: 36362387. Pmcid: PMC9653598.
  • Maccioni P, Kaczanowska K, McDonald P, Colombo G. Development of Partial Tolerance to the Suppressing Effect of the Positive Allosteric Modulator of the GABAB Receptor, KK-92A, on Alcohol Self-Administration in Rats. Alcohol Alcohol. 2022 Nov.57(6):706-711. Pubmedid: 35589119.
  • Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Replicative Instability Drives Cancer Progression. Biomolecules. 2022 Oct.12(11). Pubmedid: 36358918. Pmcid: PMC9688014.
  • Pezacki AT, Matier CD, Gu X, Kummelstedt E, Bond SE, Torrente L, Jordan-Sciutto KL, DeNicola GM, Su TA, Brady DC, Chang CJ. Oxidation state-specific fluorescent copper sensors reveal oncogene-driven redox changes that regulate labile copper(II) pools. Proc Natl Acad Sci U S A. 2022 Oct.119(43):e2202736119. Pubmedid: 36252013. Pmcid: PMC9621372.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
  • Smalley I, Smalley KSM. Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma. Cancer Res. 2022 Sep.82(18):3198-3200. Pubmedid: 36111402.
  • Ravichandran M, Hu J, Cai C, Ward NP, Venida A, Foakes C, Kuljanin M, Yang A, Hennessey CJ, Yang Y, Desousa BR, Rademaker G, Staes AAL, Cakir Z, Jain IH, Aguirre AJ, Mancias JD, Shen Y, DeNicola GM, Perera RM. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Cancer Discov. 2022 Sep.12(9):2198-2219. Pubmedid: 35771494. Pmcid: PMC9444964.
  • Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030. Pmcid: PMC9528501.
  • Ward NP, DeNicola GM. Long-sought mediator of vitamin K recycling discovered. Nature. 2022 Aug.608(7924):673-674. Pubmedid: 35922487.
  • Jiang C, Ward NP, Prieto-Farigua N, Kang YP, Thalakola A, Teng M, DeNicola GM. Corrigendum to "A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer" [Redox Biol. 54 (2022) 102358]. Redox Biol. 2022 Aug.54:102393. Pubmedid: 35794066. Pmcid: PMC9287741.
  • Jiang Q, Sudalagunta P, Silva MC, Canevarolo RR, Zhao X, Ahmed KT, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS, Zhang W. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation. Bioinformatics. 2022 Aug.38(16):4002-4010. Pubmedid: 35751591.
  • Jiang C, Ward NP, Prieto-Farigua N, Kang YP, Thalakola A, Teng M, DeNicola GM. A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer. Redox Biol. 2022 Aug.54:102358. Pubmedid: 35667246. Pmcid: PMC9168196.
  • Somarelli JA, DeGregori J, Gerlinger M, Heng HH, Marusyk A, Welch DR, Laukien FH. Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. Med Oncol. 2022 Jul.39(9):137. Pubmedid: 35781581. Pmcid: PMC9252949.
  • Farrokhian N, Maltas J, Dinh M, Durmaz A, Ellsworth P, Hitomi M, McClure E, Marusyk A, Kaznatcheev A, Scott JG. Measuring competitive exclusion in non-small cell lung cancer. Sci Adv. 2022 Jul.8(26):eabm7212. Pubmedid: 35776787.
  • Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DLJ. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm. 2022 Jun.37(5):355-363. Pubmedid: 35695807. Pmcid: PMC9242709.
  • Wang X, Li Y, Li Z, Lin S, Wang H, Sun J, Lan C, Wu L, Sun D, Huang C, Singh PK, Hempel N, Trebak M, DeNicola GM, Hao J, Yang S. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Cancer Res. 2022 Jun.82(12):2254-2268. Pubmedid: 35413105. Pmcid: PMC9203979.
  • Vander Velde R, Shaffer S, Marusyk A. Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. Trends Cancer. 2022 Jun.8(6):456-466. Pubmedid: 35307314.
  • Pillai S, Mahmud I, Mahar R, Griffith C, Langsen M, Nguyen J, Wojtkowiak JW, Swietach P, Gatenby RA, Bui MM, Merritt ME, McDonald P, Garrett TJ, Gillies RJ. Lipogenesis mediated by OGR1 regulates metabolic adaptation to acid stress in cancer cells via autophagy. Cell Rep. 2022 May.39(6):110796. Pubmedid: 35545051. Pmcid: PMC9137419.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Li J, DeNicola GM, Ruffell B. Metabolism in tumor-associated macrophages. Int Rev Cell Mol Biol. 2022 Apr.367:65-100. Pubmedid: 35461660. Pmcid: PMC9094395.
  • Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Apr.38(9):2645-2647. Pubmedid: 35258565.
  • Foo J, Basanta D, Rockne RC, Strelez C, Shah C, Ghaffarian K, Mumenthaler SM, Mitchell K, Lathia JD, Frankhouser D, Branciamore S, Kuo YH, Marcucci G, Vander Velde R, Marusyk A, Hang S, Hari K, Jolly MK, Hatzikirou H, Poels K, Spilker M, Shtylla B, Robertson-Tessi M, Anderson ARA. Roadmap on plasticity and epigenetics in cancer. Phys Biol. 2022 Apr.19(3). Pubmedid: 35078159. Pmcid: PMC9190291.
  • Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LT, Van Aelst L, Xi D, Yuan P, Brady DC, Chang CJ. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022 Feb.22(2):102-113. Pubmedid: 34764459. Pmcid: PMC8810673.
  • Bailey T, Nieto A, McDonald P. Inhibition of the Monocarboxylate Transporter 1 (MCT1) Promotes 3T3-L1 Adipocyte Proliferation and Enhances Insulin Sensitivity. Int J Mol Sci. 2022 Feb.23(3). Pubmedid: 35163825. Pmcid: PMC8836706.
  • Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone PAS. Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy. Can J Urol. 2022 Feb.29(1):10976-10978. Pubmedid: 35150217.
  • Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2022 Feb.22(2):e214-e223. Pubmedid: 34384695.
  • Torrente L, DeNicola GM. Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges. Annu Rev Pharmacol Toxicol. 2022 Jan.62:279-300. Pubmedid: 34499527.
  • Mecozzi N, Nenci A, Vera O, Bok I, Falzone A, DeNicola GM, Karreth FA. Genetic tools for the stable overexpression of circular RNAs. RNA Biol. 2022 Jan.19(1):353-363. Pubmedid: 35289721. Pmcid: PMC8928841.